NASDAQ$IVVD
Invivyd Inc · Q1 2025 earnings
Q1 2025 earnings · · Before market open · Investor relations
Briefing
Invivyd reported lower revenue compared to Q4 but narrowed its net loss significantly in Q1 2025.
The company generated $11.3 million in PEMGARDA revenue while reducing R&D expenses and net loss compared to the same period last year. Invivyd remains focused on reaching near-term profitability and bolstering its antibody pipeline.
- PEMGARDA net product revenue was $11.3 million in Q1 2025, down from $13.8 million in Q4 2024.
- Net loss narrowed to $16.3 million, significantly improved from $43.5 million in Q1 2024.
- Cash and cash equivalents stood at $48.1 million at quarter-end.
- R&D expenses dropped by more than 65% YoY due to lower clinical and manufacturing costs.
Headline financials
Revenue & EPS history
Invivyd · Revenue · Quarterly
$11.3M
Forward guidance
Invivyd aims to achieve profitability in the first half of 2025, supported by revenue growth, expense control, and potential access to additional funding.
Tailwinds
- Targeting near-term profitability by H1 2025
- Re-acceleration of PEMGARDA sales observed in early Q2
- Secured $30 million term loan facility for additional runway
- VYD2311 Phase 1 data expected later in Q2 2025
- Ongoing expansion of pipeline beyond SARS-CoV-2
Headwinds
- Revenue declined sequentially from Q4 2024
- FDA declined EUA expansion request for PEMGARDA treatment use
- SG&A expenses increased YoY due to commercialization ramp-up
- Cash reserves decreased from $69.3M to $48.1M
- Uncertainty around continued EUA status for PEMGARDA
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 18 quarterly earnings reports · overlaid with Q1 2025
-1.7%
Avg return
Earnings day
-1.3%
Avg return
5 days after
-15.0%
Avg return
30 days after
53%
10 / 19 earnings
Positive
+18.4%
Q4 2021
Best reaction
-21.6%
Q1 2026
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -21.6% | -30.4% | — | |
| Q4 2025 | +2.4% | +7.0% | -25.1% | |
| Q3 2025 | +1.3% | +8.6% | +46.7% | |
| Q1 2025 | -15.8% | -3.2% | -5.3% | |
| Q4 2024 | +2.6% | -8.3% | -29.2% | |
| Q3 2024 | -15.2% | -13.8% | -38.5% | |
| Q2 2024 | -1.9% | -13.9% | +8.5% | |
| Q1 2024 | -10.7% | -4.0% | -33.2% | |
| Q4 2023 | +6.3% | +1.8% | -49.8% | |
| Q3 2023 | -7.9% | -1.3% | +11.8% | |
| Q2 2023 | +2.6% | +5.1% | +13.5% | |
| Q1 2023 | +1.4% | +5.6% | -8.5% | |
| Q4 2022 | -7.7% | -4.9% | -19.0% | |
| Q3 2022 | +8.8% | +6.3% | -40.2% | |
| Q2 2022 | -2.5% | +5.3% | +9.8% | |
| Q1 2022 | +7.9% | +10.9% | +11.3% | |
| Q4 2021 | +18.4% | +13.8% | -25.7% | |
| Q3 2021 | +5.5% | +4.9% | -66.8% | |
| Q2 2021 | -7.0% | -15.0% | -30.5% |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro